Assessing glioblastoma response during MR-guided radiation therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates how glioblastoma multiforme responds to treatment by using weekly low field MR imaging during standard radiotherapy. A total of 20 patients will be recruited to assess changes in tumor volume and explore the potential for predicting treatment response through radiomics analysis. Prior to the main study, up to 20 volunteers will undergo MR scans to ensure high image quality for the investigation.

Why it matters

Who can join: the full rules

Inclusion criteria patients:

Subjects fulfilling all of the following criteria are eligible for the study:

* Informed Consent as documented by signature according to Swiss law and ICH/GCP regulations before any trial specific procedures (Appendix I Informed Consent Form)
* Histologically confirmed diagnosis of GBM
* Indication for fractionated radiation therapy for GBM
* Age: ≥ 18 years old
* Gender: any
* Karnofsky performance status ≥60
* Patients who are willing and able to comply with scheduled visits, treatment, and other trial procedures

Exclusion criteria

* The presence of any one of the following criteria will lead to exclusion of the subject:
* Previous cranial radiation therapy
* Contraindications to MR examinations, e.g., non-compatible implantable device or metallic foreign bodies
* Inability to complete MR examination due to claustrophobic anxiety
* Women who are pregnant or breast feeding,
* Intention to become pregnant during the course of the study
* Lack of safe contraception, defined as: Female subjects of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases. Female subjects who are surgically sterilized / hysterectomized or post-menopausal for longer than 2 years are not considered as being of child bearing potential.
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, diabetes, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia
* Known or suspected non-compliance, drug or alcohol abuse
* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the subject
* Participation in another study with investigational drug within the 30 days preceding and during the present study
* Enrolment of the investigator, his/her family members, employees and other dependent persons

Where it's running

• University Hospital Zurich
  Zurich, Canton of Zurich, Switzerland Recruiting

Study contacts

• Study coordinator: Michael Mayinger, MD
• Email: michael.mayinger@usz.ch
• Phone: +41432530691

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• LMP744 (an indenoisoquinolone) for people with recurrent glioblastoma

  This trial will test whether the drug LMP744 can shrink tumors or slow progression in adults whose glioblastoma has returned after prior treatment.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07416188

• Adding ruxolitinib to standard radiation and temozolomide for newly diagnosed glioblastoma

  This trial will try whether adding the oral drug ruxolitinib to standard radiation and temozolomide helps adults newly diagnosed with glioblastoma.

  Recruiting at 2 sites Phase 2 Baptist Health South Florida · Miami, Florida and 1 other locations · NCT06991101

• Radiation plus tarlatamab for DLL3-expressing tumors

  This trial will test whether giving tarlatamab together with standard palliative or consolidative radiation is safe for adults with DLL3-expressing or DLL3-prevalent tumors such as melanoma, medullary thyroid cancer, sinonasal undifferentiated carcinoma, esthesioneuroblastoma, and bladder cancer.

  Recruiting at 3 sites Phase 1/2 University of Arizona · Gilbert, Arizona and 2 other locations · NCT06814496

• Using low-intensity magnetic therapy for newly diagnosed glioblastoma patients

  This study is testing whether a low-intensity magnetic therapy device can safely help people who have just been diagnosed with glioblastoma.

  Recruiting at 6 sites BioTex, Inc. · Stuttgart, Baden-Wurttemberg and 5 other locations · NCT06533163

• Evaluating Bevacizumab with Focused Ultrasound for Recurrent Glioblastoma

  This study is testing if adding focused ultrasound to the standard treatment of Bevacizumab can help people with recurrent glioblastoma feel better and live longer.

  Recruiting at 2 sites Phase 3 NaviFUS Corporation · Taipei and 1 other locations · NCT06496971

• Using FET-PET fused with MRI to better map and treat glioblastoma

  This will try using FET-PET combined with contrast MRI to better identify tumor tissue and guide surgery and treatment for adults with a single, newly diagnosed glioblastoma.

  Recruiting Copernicus Memorial Hospital · Lodz, Łódź Voivodeship · NCT06466031

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.